Serik A. Baidurin

Serik A. Baidurin

Auto-generated profile, based on publicly available information

Serik A. Baidurin

NCJSC «Astana medical university», Astana, Republic of Kazakhstan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
AIAltynay T. Imangaliyeva
Altynay T. Imangaliyeva
NSNurgul Sikhayeva
Nurgul Sikhayeva
SBSerik A. Baidurin
Serik A. Baidurin
BSBibigul A. Suleimenova
Bibigul A. Suleimenova
ARAliya Romanova
Aliya Romanova
ABAidos Bolatov
Aidos Bolatov
Background: Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) are highly prevalent in Kazakhstan, with metformin as the first‐line therapy. However, individual variability in treatment response and adverse effects necessitates pharmacogenetic evaluation. This study is aimed at assessing the clinical and biochemical efficacy of metformin in Kazakh patients with MetS, T2DM, or both and at identifying pharmacogenetic markers associated with treatment response and tolerability. Methods: A prospective cohort of 206 Kazakh patients (MetS: n = 44, MetS + T2DM: n = 123, T2DM: n = 39) was enrolled. Clinical, anthropometric, and biochemical parameters were measured at baseline and 3 months after metformin therapy. Ten SNPs previously implicated in metformin pharmacogenetics were genotyped. Associations with treatment efficacy (HbA1c reduction and glycemic goal achievement) and dyspeptic side effects were analyzed using ANOVA, logistic regression, and chi‐square tests. Results: Metformin significantly improved weight, blood pressure, glucose, and lipid profiles across all groups. The SNPs rs2289669 (SLC47A1) and rs3792269 (CAPN10) were significantly associated with greater HbA1c reduction, glycemic goal achievement, and risk of dyspepsia. The rs11212617 variant showed a modest association with treatment efficacy. Conclusions: Metformin is effective across diverse metabolic phenotypes in the Kazakh population, with genetic variation contributing to interindividual differences in efficacy and tolerability. Pharmacogenetic profiling may improve personalized diabetes care.

28 February 2024 in Наука и здравоохранение
Verified
Journal Article
Open access
АШАхметжанова Ш.к.
Ахметжанова Ш.к.
БСБайдурин С.а.
Байдурин С.а.
ЖШЖукушева Ш.т.
Жукушева Ш.т.
КСКазкенова С.
Казкенова С.
АГАлиайдар Г.
Алиайдар Г.
Өзектілігі. Covid-19 коронавирустық инфекциясы эпидемиялық ошағы Хубэй провинциясының Ухань қаласында (Қытай, 2019 жылғы желтоқсан) басталғаны белгілі. 2022 жылдың 14 сәуірінде бүкіл әлем бойынша коронавирустық инфекцияның 501 миллионнан астам жағдайы тіркелді және 6,2 миллионнан астам өлім расталды, бұл Covid-19 пандемиясын тарихтағы ең өлімге әкелетіндердің біріне айналдырды. Коронавирустық инфекцияның пандемиясы жұқпалы емес соматикалық патологияның, көбінесе жүрек-қан тамырлары ауруларының таралуын арттырды. Мақсаты. COVID-19 коронавирустық инфекциясының артериялық гипертензия ағымы мен семіздікке әсерін зерттеу. Іздеу стратегиясы. Әдебиет деректерін талдауды біз Cochrane Library базаларында, 2019 жылдың желтоқсанынан 2024 жылдың ақпанына дейін аралықта Pubmed іздеу базаларында жүргіздік, 2018 гайдлайндары AГ және семіздіктің таралуын анықтау үшін пайдаланылды. Қосу критерилері: жүйелі шолулар, проспективті және ретроспективті когорттық зерттеулер. Қоспау критерийлері: 18 жасқа дейінгі балаларға КВИ-дің әсері мәселелерін қарастыратын мақалалар, жүктілілік, қатерлі ісіктер, covid-19-ға дейінгі миокард инфарктісі, инсульт, аритмия, созылмалы бүйрек аурулары соңғы сатылары, аутоиммунды аурулардың болуы. 500-ден астам дереккөз табылды, талдау үшін 93 дереккөз таңдалды Нәтижелері. Ағзаға жаңа вирустың енуі нәтижесінде ренин-ангиотензин-альдостерон жүйесінің (РААС) компоненттерінің зақымдануын ескере отырып, әлемдік медициналық қоғамдастықта АГ бар науқастардың SARS-CoV-2 инфекциясына жоғары сезімталдығы туралы гипотеза пайда болды. Сонымен қатар, AГ бар науқастарда COVID-19 коронавирустық инфекциясы әсерінен жүрек-қан тамырлары қауіп қатерлері артады, өйткені қан қысымы деңгейінің тұрақсыздығы, қан қысымының тәуліктік профиліндегі айқын өзгерістер, эндотелий дисфункциясы мен тромбоздық асқынулар анықталады Relevance. It is known that the epidemic flare-up began in Wuhan, Hubei Province (China, December 2019). As of April 14, 2022, over 501 million cases of coronavirus contamination have been detailed around the world and more than 6.2 million passings have been confirmed, making the Covid-19 widespread one of the deadliest in history. The widespread of coronavirus contamination has caused an increment within the prevalence of non-communicable physical pathology, to a more prominent degree cardiovascular illnesses. Goal. To consider the impact of COVID-19 coronavirus contamination on the characteristics of hypertension and obesity. Search strategy. We analyzed literature data in search databases: Cochrane Library, from December 2019 to February 2024 in Pubmed databases, 2018 guidelines were used to determine the prevalence of AH and obesity. Inclusion criteria: systematic reviews, prospective and retrospective cohort studies. Exclusion criteria: articles managing with the impacts of CVI on children under 18 years of age, pregnancy, malignant neoplasms, myocardial infarction, stroke, arrhythmias before COVID-19, chronic kidney disease at a late stage, the presence of autoimmune diseases. More than 500 sources were found, and 93 sources were selected for analysis. Results. Taking into account the damage to the components of the renin-angiotensin-aldosterone system (RAAS) as a result of the penetration of a new virus into the body, a hypothesis has developed within the global medical community around the next susceptibility of patients with hypertension to SARS-CoV-2 infection. At the same time, in patients with hypertension against the background of COVID-19 coronavirus infection, the cardiovascular risk increases, since destabilization of blood pressure levels, pronounced changes within the every day blood pressure profile, endothelial dysfunction with thrombotic complications are revealed. Актуальность. Известно, что эпидемическая вспышка коронавирусной инфекции Covid-19 началась в городе Ухань, провинции Хубэй (Китай, декабрь 2019 год). По состоянию на 14 апреля 2022 года было зарегистрировано свыше 501 млн случаев коронавирусной инфекции по всему миру и подтверждено более 6,2 млн летальных исходов, что делает пандемию Covid-19 одной из самых смертоносных в истории. Пандемия коронавирусной инфекции вызвала...

28 August 2025 in Наука и здравоохранение
Verified
Journal Article
Open access
ASA.S. Serikova
A.S. Serikova
IMI.Y. Mukatova
I.Y. Mukatova
SBS.A. Baidurin
S.A. Baidurin
ZUZh.M. Urazalina
Zh.M. Urazalina
Chronic respiratory failure (CRF) represents a common outcome of chronic bronchopulmonary diseases and significantly influences hospitalization rates, quality of life, and mortality. Improvement in patient prognosis depends not only on the management of the underlying disease but also on the targeted correction of CRF through various modalities of respiratory support, both during exacerbations and in remission phases. The principal strategies for respiratory support include oxygen therapy and non-invasive ventilation (NIV). The primary indication for long-term non-invasive ventilatory support is chronic hypercapnic respiratory failure. Prolonged use of NIV has been shown to improve pulmonary function, enhance gas exchange, increase exercise tolerance, reduce dyspnea, improve quality of life, decrease the risk of rehospitalization, and ultimately enhance survival. Currently, there is insufficient evidence regarding the initiation of non-invasive respiratory support in the outpatient setting for patients with chronic bronchopulmonary pathology. Only a limited number of studies with small cohorts have investigated home initiation of NIV in patients with hypercapnic CRF due to chronic obstructive pulmonary disease (COPD). These studies have demonstrated comparable efficacy in terms of arterial carbon dioxide levels when compared to in-hospital initiation. There is a clear need to expand research in this area by increasing sample sizes, which would allow for the development of evidence-based guidelines for outpatient NIV initiation. At present, there are no standardized recommendations regarding the timing of NIV initiation, patient selection criteria, or parameters for monitoring the effectiveness of non-invasive respiratory support in the ambulatory setting. Moreover, there is no consensus on evaluating the effectiveness of outpatient management of chronic hypercapnic respiratory failure. Thus, the development of clinical algorithms and evidence-based recommendations for the initiation, monitoring, and long-term management of patients receiving non-invasive ventilatory support in the outpatient setting remains a pressing issue. Хроническая дыхательная недостаточность (ХДН) является исходом хронических бронхолегочных заболеваний и определяет частоту госпитализаций, качество жизни и летальность. Улучшение прогноза пациентов обусловлено не только лечением основного заболевания, но и коррекцией непосредственно ХДН различными вариантами респираторной поддержки, как при обострении, так и в период ремиссии. Основные направления респираторной поддержки включают в себя применение кислородотерапии и неинвазивной вентиляции легких (НИВЛ). Показаниями для назначения длительной неинвазивной респираторной поддержки является хроническая гиперкапническая дыхательная недостаточность. Долгосрочная НИВЛ может улучшить функцию легких, газообмен, повысить толерантность к физическим нагрузкам, уменьшить одышку, улучшить качество жизни, снизить риск повторной госпитализации и повысить выживаемость. На сегодня, данных об инициации неинвазивной респираторной поддержки амбулаторно у пациентов с бронхолегочными заболеваниями недостаточно. Существуют единичные исследования с небольшим количеством пациентов с гиперкапнической ХДН на фоне ХОБЛ по началу неинвазивной респираторной поддержки в домашних условиях. Эти исследования продемонстрировали равнозначную эффективность с началом терапии в стационаре по уровню углекислого газа в артериальной крови. Необходимо расширение подобных исследований, увеличения группы наблюдения, что позволит создать рекомендации для инициации НИВЛ в амбулаторных условиях. На данный момент нет четких рекомендаций по срокам инициации НИВЛ, критериям отбора пациентов и контроля эффективности амбулаторной неинвазивной респираторной поддержки. Нет единой рекомендации по оценке эффективности хронической гиперкапнической дыхательной недостаточности на амбулаторном этапе. Актуальным является разработка алгоритмов и рекомендаций по инициации, контролю и ведению таких пациентов на амбулаторном этапе. Созылмалы тыныс жеткіліксіздігі (СТЖ) созылмалы бронхөкпелік аурулардың ақырғы кезеңі болып табылады және ол ауруханаға жатқызу жиілігін, өмір...

14 October 2026 in Clinical Hemorheology and Microcirculation
Verified
Journal Article
Closed access
AKAidos Kenzhin
Aidos Kenzhin
SASaniya Abdrakhmanova
Saniya Abdrakhmanova
SBSerik Baidurin
Serik Baidurin
ZBZharas Bibekov
Zharas Bibekov
MAMariya Akhayeva
Mariya Akhayeva
YMYevgeniy Merenkov
Yevgeniy Merenkov
Background: Platelet concentrates are conventionally stored at room temperature (20–24°C), which preserves platelet viability but is associated with progressive metabolic deterioration and increased risk of bacterial contamination. Cold storage (4°C) has re-emerged as a potential alternative strategy; however, its impact on platelet metabolism, activation, and hemostatic function during extended storage remains incompletely characterized. Aim: To evaluate metabolic and functional changes in apheresis platelet concentrates during storage under cold and room temperature conditions. Methods: Apheresis platelet concentrates obtained from two healthy donors were stored in platelet additive solution with or without pathogen inactivation. Platelets were stored at 20–24°C (up to 7 days) or 4°C (up to 21 days). Metabolic parameters (pH, glucose, lactate), activation markers (CD62P, Annexin V), and hemostatic function (thromboelastography) were assessed at predefined time points. Because this was an exploratory pilot study with two independent donors, the analysis was primarily descriptive and no inferential statistical comparisons were performed. Results: Cold storage was associated with slower glucose consumption and lower lactate accumulation during the early storage period, accompanied by a progressive decline in pH during prolonged storage. Cold-stored platelets showed increased CD62P expression and phosphatidylserine exposure, as reflected by Annexin V binding, particularly during prolonged storage. Thromboelastographic analysis showed relative preservation of clot strength during the first 7 days of cold storage, with mean maximum amplitude values remaining approximately 72–79 mm during this period. Conclusion: Cold storage was associated with distinct metabolic and functional changes, including slower early glucose consumption, lower lactate accumulation, increased platelet activation and phosphatidylserine exposure, and relative preservation of clot strength during the first 7 days. Given the exploratory design and limited sample size, these findings should be considered preliminary and require confirmation in larger experimental and clinical studies.